Enlivex Therapeutics Ltd (ENLV)

$1.15 +0.11 (10.58%)
Market Cap 239.76M
Revenue (ttm) 0.00
Net Income (ttm) -15.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 855,299
Avg Vol 487,302
Day's Range N/A - N/A
Shares Out 237.38M
Stochastic %K 21%
Beta 1.63
Analysts Sell
Price Target $13.00

Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 620 8072
Address:
14 Einstein Street, Ness Ziona, Israel
PSM_EmpowerTrading
PSM_EmpowerTrading Feb. 27 at 2:26 PM
🌅 Watchlist part 2 ✅ $XWEL mid $1.50 support, if above $1.80, have potential to $2.00 / $2.40 ✅ $ZTEK low $0.60 support, if above $0.85, have potential to $1.00 / $1.20 ✅ $BTOC low $0.40 support, if above $0.50, have potential to $0.60 / $0.70 ✅ $VEEA mid $0.50 support, if above $0.75, have potential to $0.90 / $1.20 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⏳ $ENLV VIVS still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Feb. 27 at 4:40 AM
🌅 Watchlist part 2 ✅ $CDIO low $7 support, if above $7.50, have potential to $8 / $8.50 ✅ $ZTEK low $0.60 support, if above $0.85, have potential to $1.00 / $1.20 ✅ $IXHL 1/30 reverse split, new price ~ $5.10 🚨 The above tickers are not ideal for swing accumulation at current price ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $ENLV $VIVS still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
Safran18
Safran18 Feb. 24 at 3:41 PM
$ENLV on Tel Aviv exchange published the name change . To enlivex ltd
0 · Reply
WheresHunter
WheresHunter Feb. 24 at 2:55 PM
$ENLV what's happening here?
0 · Reply
InvestForDaKids
InvestForDaKids Feb. 24 at 2:55 PM
$ENLV let’s go $17
0 · Reply
cled
cled Feb. 24 at 2:54 PM
$ENLV
0 · Reply
hitmongreen
hitmongreen Feb. 24 at 2:45 PM
$ENLV 🔥
0 · Reply
wgreystone
wgreystone Feb. 21 at 11:00 PM
$IBRX Sepsis is huge market and currently no viable treatment approved. $ENLV had a very promising cell therapy but unfortunately failed in P2 clinicsl trial. Would be interesting to see how Anktiva and NK cells can help in this indication.
2 · Reply
mbelect
mbelect Feb. 21 at 3:40 AM
$ENLV garbage
0 · Reply
DarlenePrice1026
DarlenePrice1026 Feb. 18 at 12:59 PM
$ENLV Biotech with novel approach; early-stage risk elevated.
0 · Reply
Latest News on ENLV
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Feb 10, 2026, 8:00 AM EST - 19 days ago

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Jan 26, 2026, 8:00 AM EST - 4 weeks ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Jan 23, 2026, 8:00 AM EST - 5 weeks ago

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum

Jan 14, 2026, 11:46 AM EST - 6 weeks ago

Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Dec 4, 2025, 8:00 AM EST - 3 months ago

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Nov 24, 2025, 10:00 AM EST - 3 months ago

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Nov 24, 2025, 7:55 AM EST - 3 months ago

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nov 24, 2025, 6:40 AM EST - 3 months ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Oct 28, 2025, 8:15 AM EDT - 4 months ago

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 29, 2025, 8:15 AM EDT - 5 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 11, 2025, 8:00 AM EDT - 6 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Sep 9, 2025, 8:00 AM EDT - 6 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 18, 2025, 7:45 AM EDT - 6 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Aug 14, 2025, 8:30 AM EDT - 7 months ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jul 28, 2025, 8:30 AM EDT - 7 months ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 10, 2025, 8:30 AM EDT - 9 months ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025, 8:00 AM EDT - 10 months ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 23, 2025, 8:30 AM EDT - 11 months ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 21, 2025, 8:30 AM EDT - 11 months ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 11 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 1 year ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 1 year ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Feb 18, 2025, 6:20 AM EST - 1 year ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 1 year ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 26, 2024, 10:15 AM EST - 1 year ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nov 14, 2024, 8:00 AM EST - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 30, 2024, 9:00 AM EDT - 1 year ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 16, 2024, 7:50 AM EDT - 2 years ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 2:58 PM EDT - 2 years ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Apr 11, 2024, 8:05 AM EDT - 2 years ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 22, 2024, 10:50 AM EDT - 2 years ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 26, 2024, 8:30 AM EST - 2 years ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Feb 21, 2024, 8:30 AM EST - 2 years ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Jan 17, 2024, 8:00 AM EST - 2 years ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Dec 20, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 31, 2023, 8:04 AM EDT - 2 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

May 8, 2023, 8:00 AM EDT - 3 years ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 3 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 17, 2023, 8:00 AM EDT - 3 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

PSM_EmpowerTrading
PSM_EmpowerTrading Feb. 27 at 2:26 PM
🌅 Watchlist part 2 ✅ $XWEL mid $1.50 support, if above $1.80, have potential to $2.00 / $2.40 ✅ $ZTEK low $0.60 support, if above $0.85, have potential to $1.00 / $1.20 ✅ $BTOC low $0.40 support, if above $0.50, have potential to $0.60 / $0.70 ✅ $VEEA mid $0.50 support, if above $0.75, have potential to $0.90 / $1.20 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⏳ $ENLV VIVS still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
1 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Feb. 27 at 4:40 AM
🌅 Watchlist part 2 ✅ $CDIO low $7 support, if above $7.50, have potential to $8 / $8.50 ✅ $ZTEK low $0.60 support, if above $0.85, have potential to $1.00 / $1.20 ✅ $IXHL 1/30 reverse split, new price ~ $5.10 🚨 The above tickers are not ideal for swing accumulation at current price ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $ENLV $VIVS still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
Safran18
Safran18 Feb. 24 at 3:41 PM
$ENLV on Tel Aviv exchange published the name change . To enlivex ltd
0 · Reply
WheresHunter
WheresHunter Feb. 24 at 2:55 PM
$ENLV what's happening here?
0 · Reply
InvestForDaKids
InvestForDaKids Feb. 24 at 2:55 PM
$ENLV let’s go $17
0 · Reply
cled
cled Feb. 24 at 2:54 PM
$ENLV
0 · Reply
hitmongreen
hitmongreen Feb. 24 at 2:45 PM
$ENLV 🔥
0 · Reply
wgreystone
wgreystone Feb. 21 at 11:00 PM
$IBRX Sepsis is huge market and currently no viable treatment approved. $ENLV had a very promising cell therapy but unfortunately failed in P2 clinicsl trial. Would be interesting to see how Anktiva and NK cells can help in this indication.
2 · Reply
mbelect
mbelect Feb. 21 at 3:40 AM
$ENLV garbage
0 · Reply
DarlenePrice1026
DarlenePrice1026 Feb. 18 at 12:59 PM
$ENLV Biotech with novel approach; early-stage risk elevated.
0 · Reply
PhantomStrike
PhantomStrike Feb. 18 at 7:11 AM
$ENLV Enlivex develops immunotherapy for sepsis and oncology, facing clinical-stage pipeline with binary data readouts [citation:historical].
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 4:00 PM
$ENLV Current Stock Price: $1.09 Contracts to trade: $1.0 ENLV Feb 20 2026 Call Entry: $0.10 Exit: $0.16 ROI: 57% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ptaylor2112
ptaylor2112 Feb. 13 at 3:31 PM
$ENLV I'm not sure why they didn't do a press release, but here are the results of the special meeting: "On February 3, 2026, Enlivex Therapeutics Ltd... held an Extraordinary General Meeting of Shareholders of the Company... At the Meeting, the shareholders voted on and approved, by the applicable required majority, each of the proposals that were described in the Company’s Notice and Proxy Statement for the Meeting..." This is from the 6-K dated Feb 5, 2026 https://enlivex.com/investors/sec-filings/
2 · Reply
ptaylor2112
ptaylor2112 Feb. 13 at 3:19 PM
$ENLV Schwab is now paying 164.5% to borrow my shares.
1 · Reply
Stackdoe101
Stackdoe101 Feb. 12 at 1:20 AM
$AR $FLEX $POST $PLMR $ENLV
0 · Reply
JimmyBobby49
JimmyBobby49 Feb. 6 at 1:59 PM
$ENLV Crypto drops and RAIN presses onward😎
0 · Reply
WebwallXii
WebwallXii Feb. 6 at 12:38 PM
$ENLV $VEEE $CCHH $ISPC next $ELPW
0 · Reply
BullButter23
BullButter23 Feb. 6 at 12:36 PM
Watchlist: $ELPW 👀 0 shares available to short Cost to borrow 701.60% $ENLV 0 shares available 442.67% CTB $VEEE 0 shares available 441.85% CTB $CCHH 0 shares available 216.82% CTB $LIMN 0 shares available 41.32%
0 · Reply
InvestForDaKids
InvestForDaKids Feb. 6 at 2:06 AM
$ENLV let’s go $88
0 · Reply
Safran18
Safran18 Feb. 5 at 7:32 AM
$ENLV
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 4:13 AM
$ENLV RSI: 65.75, MACD: 0.0538 Vol: 0.11, MA20: 0.99, MA50: 0.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jan. 31 at 6:44 PM
$ENLV crypto’s falling…
0 · Reply